WordNet

a substance that retards or stops an activity
(biology) any agency bringing about activation; a molecule that increases the activity of an enzyme or a protein that increases the production of a gene product in DNA transcription
an inactive form of plasmin that occurs in plasma and is converted to plasmin by organic solvents

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 血栓溶解異常による血栓性および出血性疾患 thrombotic and hemorrhagic disorders due to abnormal fibrinolysis
2. 線溶マーカーおよび心血管リスク fibrinolytic markers and cardiovascular risk
3. 止血の概要 overview of hemostasis
4. 妊娠中の先天性血栓性素因 inherited thrombophilias in pregnancy
5. 下肢末梢動脈疾患の症状を治療するための試験的治療 investigational therapies for treating symptoms of lower extremity peripheral artery disease

Fortenberry YM.SourceJohns Hopkins University School of Medicine, Division of Hematology/Department of Pediatrics , 720 Rutland Avenue Ross 1120, Baltimore, MD 21205 , USA +1 410 955 8208 ; yforten1@jhmi.edu.
Expert opinion on therapeutic patents.Expert Opin Ther Pat.2013 Jul;23(7):801-15. doi: 10.1517/13543776.2013.782393. Epub 2013 Mar 25.
Introduction: Plasminogen activator inhibitor-1 (PAI-1), the serine protease inhibitor (serpin), binds to and inhibits the plasminogen activators-tissue-type plasminogen activator (tPA) and the urokinase-type plasminogen activator (uPA). This results in both a decrease in plasmin production and a de
PMID 23521527

Biomarkers for the clinical management of breast cancer: international perspective.

Patani N, Martin LA, Dowsett M.SourceThe Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, United Kingdom.
International journal of cancer. Journal international du cancer.Int J Cancer.2013 Jul;133(1):1-13. doi: 10.1002/ijc.27997. Epub 2013 Feb 8.
The higher incidence of breast cancer in developed countries has been tempered by reductions in mortality, largely attributable to mammographic screening programmes and advances in adjuvant therapy. Optimal systemic management requires consideration of clinical, pathological and biological parameter
PMID 23280579

Phipps MS, Zeevi N, Staff I, Fortunato G, Kuchel GA, McCullough LD.SourceStroke Center at Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA; Department of Neurology, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030, USA. Electronic address: mphipps@calalum.org.
Archives of gerontology and geriatrics.Arch Gerontol Geriatr.2013 Jun 28. pii: S0167-4943(13)00095-2. doi: 10.1016/j.archger.2013.05.007. [Epub ahead of print]
Pre-exposure to 3-hydroxy-3-methylgutaryl-coenzyne A reductase inhibitors (statins) appears to improve outcomes in patients with acute ischemic stroke (AIS). Whether this extends to patients over 80 is not known. Patients ≥80 years of age with AIS were retrospectively reviewed from the stroke regi
PMID 23815970

峰松一夫
脳卒中 36(2), 129-130, 2014
要旨：脳梗塞急性期治療において，抗血栓療法は主要な位置を占めている．抗血栓薬は血栓溶解薬，抗血小板薬，抗凝固薬に大別され，製剤の種類も多い．しかしながら，急性期治療においてエビデンスレベルが高いのは血栓溶解薬alteplase と抗血小板薬aspirin のみである．抗凝固薬に至っては，海外ではむしろ否定的な意見が多い．最近，alteplase の治療可能時間の延長，脳梗塞急性期の抗血小板薬多剤併 …
NAID 130004873600

Eugenol Ameliorates Hepatic Steatosis and Fibrosis by Down-Regulating SREBP1 Gene Expression via AMPK-mTOR-p70S6K Signaling Pathway

Jo Hee Kyung,Kim Go Woon,Jeong Kyung Ju,Kim Do Yeon,Chung Sung Hyun
Biological and Pharmaceutical Bulletin 37(8), 1341-1351, 2014
… These effects were all reversed in the presence of specific inhibitors of CAMKK, AMPK or mTOR. … Gene expressions of fibrosis marker protein such as α-smooth muscle actin (α-SMA), collagen type I (Col-I) and plasminogen activator inhibitor-1 (PAI-1) were also significantly reduced by 36%, 63% and 40% in eugenol-treated mice. …
NAID 130004677544

Tumor necrosis factor α stimulates expression and secretion of urokinase plasminogen activator in human dental pulp cells

Narita Takanori,Muromachi Koichiro,Kamio Naoto,Nakao Sumi,Matsushima Kiyoshi,Hashizume Hideki
Journal of Oral Science 54(4), 329-336, 2012
… Plasminogen activator (PA) is the enzyme responsible for converting plasminogen to its active form, plasmin, which is involved in various physiological and pathological phenomena. … The expression of uPA mRNA and PA secretion stimulated by TNF-α were reduced by the tyrosine kinase inhibitors herbimycin A and genistein, and by the NFκB inhibitor pyrrolidine dithiocarbamate, but were augmented by the tyrosine phosphatase inhibitor sodium orthovanadate. …
NAID 130003318541